IUSCC-0551; A Phase I/Ib Open Label Dose Finding Study to Evaluate Safety Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination with Vorinostat in Patients with Advanced Renal or Urothelial Cell Carcinoma

Study Overview

The purpose of this study is to determine the safety profile of combining two drugs, pembrolizumab and vorinostat, in bladder and kidney cancers.

Study Description

The purpose of this study is to determine the safety profile of combining two drugs, pembrolizumab and vorinostat, in bladder and kidney cancers.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1510440598
  • Research Study Identifier: TX5640
  • Principal Investigator: Roberto Pili, MD

Recruitment Status

Closed
Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.